The Serum Institute of India has been at the forefront of producing the lower-cost AstraZeneca coronavirus shot
The SII CEO, who has been in the UK on an extended stay to evade alleged threats in India over the ever-increasing demand for COVID-19 vaccines, has said he will return in a few days
Not possible to ramp up production overnight, says SII's Adar Poonawalla as pressure to supply COVID-19 vaccine builds
His comments come hours after the Ministry of Health and Family Welfare earlier on Monday rebuffed media reports alleging that the Centre has not placed fresh orders for COVID-19 vaccines
COVID-19 vaccine: Adar Poonawalla claims 'aggressive calls from India's powerful' as reason for leaving India
The SII CEO's comments come in the backdrop of the ever-increasing demand in India as the country battles through a devastating second wave of the coronavirus pandemic
COVID-19 vaccine: In a 'philanthropic gesture', SII reduces Covishield price to Rs 300 per dose for states
This follows widespread criticism of the pricing policy of the SII, which sold the initial doses of Covishield to the Central Government at Rs 150 per dose
The economist's comments comes in the backdrop of the Serum Institute of India’s hiking the price of its COVISHIELD vaccine. The Centre, meanwhile, has asked both SII and Bharat Biotech to lower the prices of their vaccines.
Union Budget 2021: Bharat Biotech, Serum Institute of India laud higher allocation for healthcare sector
SII CEO Adar Poonawalla said that globally, spending on healthcare infrastructure and vaccines has given countries and their economies the best chance at fighting COVID-19
The company is aiming to launch the vaccine being produced in collaboration with American vaccine development company Novavax by June 2021, SII CEO Adar Poonawalla said
Meanwhile, five people died in a fire that broke out in a facility of the Serum Institute of India (SII) in Pune's Manjari area. SII is manufacturing the Oxford-AstraZeneca vaccine, 'Covishield'
Fire at Pune's Serum Institute of India leaves five dead; Covishield production unaffected, says CEO Adar Poonawalla
Meanwhile, Chief Minister Uddhav Thackeray is set to visit the facility to take stock of the situation tomorrow. The Maharashtra govt has also ordered a probe into the cause of the fire
Over 1.91 lakh healthcare, sanitary workers get COVID-19 vaccine jabs; no cases of post-vaccination hospitalisation, says Centre
The Union health ministry that the programme had been a "success" as no cases of post-vaccination hospitalisation had been reported as of 7 pm on Saturday
Narendra Modi to launch vaccination drive on 16 Jan, says Centre; over 56 lakh doses of Covishield sent to 13 cities
The Union health ministry was also quoted as saying that Modi is likely to launch the Co-WIN app, and interact with vaccine beneficiaries across the country
Covaxin trials conducted with '200% honesty', says Bharat Biotech MD; new COVID-19 cases under 20,000 for 3rd day
The global efforts to curb the spread of COVID-19 got a boost in the UK, as it became the first country to administer a vaccine against the virus
Serum institute banned from exporting Oxford-AstraZeneca's COVID-19 vaccine for several months: Adar Poonawalla
He said the vaccine can only be given to the Indian government and export of vaccines for COVAX, won’t begin until March or April.
Last month, SII had rejected allegations of serious side-effects made by a participant in the Covishield vaccine trial in Chennai. The man had also sought Rs 5 crore compensation
Poonawalla also said the SII is in the process of applying for an emergency usage licence, and that he has discussed an implementation plan with Prime Minister Modi during his visit to its Pune facility on Saturday
Studies have shown that in people with severe COVID-19, the neutrophils get strongly activated and adopt a low-density phenotype.
Fortune 40 Under 40: 2020 emerging leaders list includes Isha and Akash Ambani, Byju Raveendran, Adar Poonawalla
The 2020 Fortune 40 Under 40 list highlights 40 influential people each across five categories — finance, technology, healthcare, government and politics, and media and entertainment from around the world.
Serum Institute asked to revise protocols for Phase 2, 3 trials of Oxford COVID-19 vaccine candidate
The CDSCO expert panel also recommended that Pune-based firm's proposed clinical trial sites be distributed across India